Cutaneous T‐cell lymphoma: 2017 update on diagnosis, risk‐stratification, and management

Abstract

Disease overview: Cutaneous T-cell lymphomas are a heterogenous group of T-cell lymphoproli-

GATA‐3 in T‐cell lymphoproliferative disorders

“…Cutaneous T‐cell lymphomas (CTCL) are a heterogeneous group of extranodal lymphomas, many of which highly express GATA‐3, and its target genes, and are resistant to conventional chemotherapeutic agents, much like GATA‐3 PTCL. The chemokine receptor CCR4 is a GATA‐3 target gene (unpublished data) that is preferentially expressed by Th2 and Treg cells and plays an important role in T‐cell trafficking to the skin, and likely contributes to the primary cutaneous localization of CTCL and secondary cutaneous involvement observed in ≈50% of patients with GATA‐3 PTCL (unpublished observation).…”

A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies

“…Patients with limited‐stage disease are best managed with skin‐directed therapies, whose goal is to induce durable remissions, while advanced‐stage patients tend to benefit more from multidisciplinary approaches that combine local and systemic therapies. In both settings, multiagent chemotherapy is generally postponed until possible, in order to avoid excessive toxicity and immunosuppression …”

“…Cutaneous T‐cell lymphomas (CTCL) are a rare group of non‐Hodgkin lymphomas characterized by the predominant localization of malignant T‐cells to the skin. The main variants of CTCL are mycosis fungoides (MF) and Sézary syndrome (SS), accounting approximately for 55% and 5% of cases, respectively . The majority of available therapies for MF/SS are not able to induce prolonged remissions or survivals: patients should be offered treatment only when required in order to reduce toxicity, following a stage‐adapted approach.…”

“…The majority of available therapies for MF/SS are not able to induce prolonged remissions or survivals: patients should be offered treatment only when required in order to reduce toxicity, following a stage‐adapted approach. In fact, the main purposes of therapies are palliation and improvement of quality of life . Moreover, despite the availability of various treatment strategies, including novel biological drugs, disease control remains challenging and often requires multiple lines of therapy …”

“…In fact, the main purposes of therapies are palliation and improvement of quality of life . Moreover, despite the availability of various treatment strategies, including novel biological drugs, disease control remains challenging and often requires multiple lines of therapy …”